Prof. Dankel is a leading expert in metabolic diseases and nutritional biochemistry, with an impressive track record of high-impact research and leadership in clinical trials. He currently heads the Research Unit for Health Surveys (RUHS) at the University of Bergen, which will host the first trial site.

RUHS brings extensive experience in executing clinical and decentralized trials and offers state-of-the-art infrastructure including a metabolic kitchen, biobank collaboration, and GDPR-compliant digital systems for participant management. This partnership sets the stage for robust, high-quality data collection and world-class regulatory standards.

This appointment follows Lifecare’s recent filing for regulatory approval to launch the clinical trial of its innovative CGM implant, marking another key milestone toward CE-marking and commercial launch.

“Engaging Prof. Dankel and RUHS is a strategic move that highlights our commitment to scientific excellence and clinical rigor,” said Joacim Holter, CEO of Lifecare ASA. “Their expertise will be instrumental as we accelerate efforts to bring our transformative technology to people living with diabetes.”